Patients after hematopoietic stem cell transplantation (HSCT) are at high risk for viral infections or reactivation. EBV, CMV, polyoma virus BK (BKV), human adenovirus (HAdV) and human herpesvirus 6 (HHV6) are the most common infections in transplanted patients. In pediatric patients, HAdV infection or reactivation is frequent due to persistence of HAdV in intestinal lymphoid cells and often associated with high morbidity and mortality. [1] [2] [3] HAdV can cause localized (respiratory, hepatic or gastrointestinal infections, kerato-conjunctivitis) or disseminated disease in immunocompromised patients. 2 The overall fatality rate can reach up to 50%. 4 The virus is a non-enveloped, double-stranded DNA virus with over 70 serotypes divided into seven species (A-G). The viral capsid is composed of three major proteins: hexon, penton base and fiber. 5 Viral clearance is usually achieved by a functional anti-HAdV T-cell response. 6, 7 Depending on conditioning regimen, the use of T-cell depleting antibodies, in vitro T-cell depletion and donor HAdV status recovery of antiviral T-cell responses may be delayed for several weeks. 4, 8, 9 Monitoring of HAdV load via PCR in blood and / or stool is recommended after HSCT to enable early or pre-emptive treatment. [10] [11] [12] Currently, cidofovir is used as standard virostatic treatment. 13 In addition, several publications demonstrate a therapeutic effect of adoptively transferred HAdVor multivirus-specific T cells. [14] [15] [16] In patients with CMV reactivation persistence of recipientderived CMV-specific T cells mediating viral control has been reported mainly after non-myeloablative conditioning regimens. 17 Here, we establish the platform to evaluate donor-/recipient provenience in virus-specific T cells and demonstrate persistence of recipient-derived HAdV-specific T cells in two pediatric patients after HSCT.
An 18-month-old boy suffered from the autosomal recessive alpha-mannosidosis, a lysosomal storage disease. His disease was characterized by discrete demyelinating disease in the white matter, hearing impairment, immunodeficiency with neutropenia, and recurrent bacterial and viral infections of the respiratory tract and ear as well as facial and skeletal abnormalities. After myeloablative conditioning with fludarabine (1 × 30 mg/m 2 , day − 9 to − 4), busulfan (2 × 2.1 mg/kg, day 7 to 4), melphalan (1 × 140 mg/m 2 , day 3) and ATG (1 × 10 mg/kg, day 3 to 1), he underwent CD34 + -selected HSCT (5 × 10 7 /kg nuclear cells, 49.5 × 10 6 /kg CD34 + cells) from a 10/10 HLA-matched unrelated donor without pharmacological immunosuppression. On day 5 after transplantation, HAdV of species A (HAdV-A31) was detected by PCR in stool and 4 days later in blood (Figure 1a) . He received three courses of standard dose cidofovir. On day 24, the viral load in stool and blood was negative. After hematological engraftment on day 16, the patient had mixed chimerism with a minimum of 70% donor cells, which rose up to a stable long-term mixed chimerism of 80% donor-derived. His other post-transplant course was mainly uneventful. 6 /kg CD34 + cells). GVHD prophylaxis was performed with cyclosporine and mycophenolate mofetil (MMF). Hematologic engraftment occurred on day 24 with a donor chimerism of 100%. 18 days after transplantation he reactivated HAdV-A31, which was detected in stool and with a low copy number identified in blood (Figure 2a ). He developed a watery diarrhea (410 stools per day). After nine courses of standard dose cidofovir, HAdV load in stool decreased and coincidentally we observed a decrease in his donor chimerism to 85%. We started monitoring of anti-HAdV-specific T-cell responses in patients' peripheral blood soon after engraftment and detection of HAdV.
HAdV-specific T-cell responses were quantified by interferon-γ (IFN-γ) ELISPOT analysis following stimulation with overlapping peptide pools derived from the HAdV5 capsid proteins penton (ppADV5 Penton) and hexon (ppADV5 Hexon) (Miltenyi Biotech, Bergisch Gladbach, Germany). 18 In both patients, HAdV-specific T cells against ppADV5 Penton and ppADV5 Hexon could be detected during HAdV reactivation paralleled by a decrease in HAdV viral load (Figures 1a and 2a) . In patient 1, the T-cell response could be, in part attributed to the known HAdV5 hexonderived immunogenic epitopes TDLGQNLLY (HLA-A*01-restricted, A01/TDL) and KPYSGTAYNAL (HLA-B*07-restricted, B07/KPY) by flow cytometry using peptide-MHC pentamer staining (Figures 1c  and 2c) . 18, 19 Both peptide-specific T-cell populations accounted for up to 3% of total CD8 + T cells. At the onset of HAdV T-cell responses, both patients showed a mixed chimerism in peripheral blood; patient 2 demonstrated a drop in chimerism from 99% to 85% (Figure 2b ). This prompted us to question whether the remaining recipient-derived fraction may be substantiated by expansion of autologous HAdV-specific T cells. The HAdV-specific T cells were enriched by magnetic separation using the IFN-γ cytokine secretion assay (Miltenyi Biotech) after short term in vitro stimulation with ppADV5 Penton or ppADV5 Hexon. DNA from isolated cells was subjected to PCR-based analysis of polymorphic short tandem repeats. Interestingly, patient 1 demonstrated an autologous/recipient fraction in hexon-(61%) and penton-(46%) specific T cells (Figure 1b) , while chimerism in whole peripheral blood was 80% donor-derived. In patient 2, HAdV-specific T cells were detectable 126 days after onset of infection. The recipient chimerism was 53% in HAdV-specific T cells (Figure 2b , 151 days after SCT), while whole-blood chimerism was 96% donor-derived. Sequential analysis revealed an increasing donor chimerism in HAdV-specific T cells over the next 2 months to 83%. This suggests that the recipient-derived HAdV-specific T-cell immunity may be transient until robust donor-derived immune responses are Peripheral blood T cells reactive to HAdV hexon (ppADV5 Hexon) and penton (ppADV5 Penton) peptide pools were quantified using IFN-γ ELISPOT assay. The HAdV-specific T cells were enriched by IFN-γ cytokine secretion assay using HLA-restricted peptides or peptide pools (hexon-and penton-derived) as stimulators followed by magnetic separation. The eluate was subjected to molecular chimerism by short tandem repeat analysis. The HAdV load was measured by weekly quantitative PCR in stool and blood. generated. In both patients, total peripheral blood donor chimerism improved to 84 and 98%, respectively, after clearance of HAdV and both patients maintain a stable graft function.
Chimerism analysis is a standard procedure after HSCT to detect early graft rejection or imminent relapse of malignant disease. Falls in donor-derived chimerism usually evoke measures to ensure stable donor engraftment such as reduction of immunosuppressive medication or administration of donor lymphocytes. Here, we demonstrate that a fall in donor chimerism in two patients with nonmalignant disease during HAdV reactivation was caused by expansion of recipient-derived HAdV-specific T cells that survived even myeloablative conditioning and contributed to control of HAdV infection early after stem cell transplantation. A fall in donor chimerism after HSCT may therefore be caused by persisting virus-specific T cells fighting against viral infections or reactivations, which is in line with earlier anecdotal observations of persistent recipient-derived CMV-specific T cells in CMV reactivation. 17, 20 Chimerism studies in cell subpopulations allow differentiation between imminent graft rejection/disease relapse and (transient) outgrowth of terminally differentiated autologous T cells fighting viral infections. Further studies should be carried out to evaluate virus-specific immune reconstitution after HSCT.
